Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Soligenix Inc SNGX

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe... see more

NDAQ:SNGX - Post Discussion

Soligenix Inc > Soligenix Extends Patent Protection for its Filovirus Vaccin
View:
Post by whytestocks on Apr 25, 2024 12:45pm

Soligenix Extends Patent Protection for its Filovirus Vaccin

JUST IN: $SNGX Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South AfricaSoligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa PR Newswire Includes thermostabilized Ebola vaccines MarVax™ and SuVax™ Includes nanoemulsion adjuvant compatible with lyophilization ...SNGX - Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities